Fosun Pharma, Shanghai Pharma Deny Interest In Stada
Fosun Pharma and Shanghai Pharma have both officially denied their involvement in any bidding battle for German company Stada, although both Chinese firms make no secret of their international expansion ambitions and have been active deal makers in the past.
You may also be interested in...
Now that Kite Pharma Inc.’s first chimeric antigen receptor T cell (CAR-T) therapy axicabtagene ciloleucel (KTE-C19) is being submitted for US FDA approval, Chairman, President and CEO Arie Belldegrun said it is the right time to think about ways to make the company’s technology available in additional markets, like Japan and China where Kite entered into partnership agreements with Daiichi Sankyo Co. Ltd. and Shanghai Fosun Pharmaceutical Group Co. Ltd., respectively.
China’s Jiangsu Hengrui Medicine is accelerating its move towards innovation by increasing investment and partnerships, as part of a strategy to shift its focus away from its traditional generic business. It is now providing substantial funding to a new US-based spinoff aiming to develop oncology biologics and immunotherapies and to act as an innovation bridge between the US and China.
China’s Shanghai Fosun Pharma has confirmed its interest in the Indian injectables firm Gland Pharma, underscoring how differentiated niche plays continue to attract buyer interest.